Geratherm Medical AG
GME
ISIN DE0005495626 / Valor 1091371
Geratherm Medical AG
UMushroom community rating:
About company
Geratherm Medical AG is an international medical technology company with a focus on developing innovative products for stroke prevention. The company has a strong academic and clinical network that complements its core competencies in mathematics, physics, and medicine. Geratherm's products, including spirometry, pulmonary function tests, and cardiopulmonary stress tests, are all developed and produced in Germany to meet high quality standards for pulmonologists, cardiologists, internists, sports medicine specialists, and natural scientists. In addition to medical devices, Geratherm also offers consumer products under the Geratherm® brand, such as clinical thermometers, blood pressure monitors, and pregnancy tests, which are available in pharmacies, retail outlets, and online shops. The company also provides innovative solutions like the MR diagnostics incubator system nomag®IC advanced for newborns and premature babies, allowing for non-invasive magnetic resonance imaging. With products for both private and professional users in various healthcare settings, Geratherm aims to meet the diverse needs of its customers worldwide.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (20.09.2025):
Geratherm Medical AG has successfully closed the first half of 2025 with a 13.2% increase in revenue compared to the previous year. The company demonstrated significant improvements in profitability metrics, reduced its net loss, and maintained a strong balance sheet despite facing regional market challenges.
Revenue Growth
In the first six months of 2025, Geratherm Medical AG reported total revenues of €8.0 million, up from €7.1 million in the same period last year. This growth was primarily driven by a 13.2% increase in sales, excluding the sale of apoplex medical technologies GmbH.
Enhanced Profitability
The company achieved a substantial improvement in profitability, with EBITDA rising to €0.6 million from €0.2 million year-over-year. The EBIT turned positive at €0.01 million, a significant turnaround from -€0.5 million in the previous year. The EBIT margin also improved to 0.1%, compared to -7.6% last year.
Regional Performance
Revenue growth was uneven across regions, with Europe increasing by 27.3%, Germany by 16.6%, and South America by a remarkable 181.4%. The USA market remained relatively flat with a 3.8% increase, while the Middle East and Other regions saw declines of 38.5% and 43.6%, respectively.
Product Segment Highlights
The Respiratory segment saw a 17.4% increase in sales, while Incubator Systems experienced a significant 91.8% growth due to successful MDR certification and reduction in backlogged orders. Conversely, the Healthcare Diagnostic segment saw a slight decline of 1.5% in revenue.
Strong Financial Position
Geratherm Medical AG maintained a robust balance sheet with a solid equity ratio of 74.7%. The company's cash flow from operations stood at €862 thousand, ensuring liquidity and financial stability for ongoing and future operations.
Outlook
The company expects continued strong demand for Respiratory products and a positive trend in Incubator Systems as orders are fulfilled. Despite extended short-time work for fever thermometer production until the end of 2025, Geratherm Medical AG remains confident in its diversified international presence to mitigate regional market fluctuations.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
22 M
Market cap (USD)
2,661
Daily traded volume (Shares)
3.5 / 3.4
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
